Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Non-Current Assets (2021 - 2026)

Zentalis Pharmaceuticals has reported Other Non-Current Assets over the past 6 years, most recently at $4.1 million for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 55.88% year-over-year to $4.1 million; the TTM value through Mar 2026 reached $4.1 million, up 55.88%, while the annual FY2025 figure was $2.6 million, 40.53% down from the prior year.
  • Other Non-Current Assets for Q1 2026 was $4.1 million at Zentalis Pharmaceuticals, up from $2.6 million in the prior quarter.
  • Over five years, Other Non-Current Assets peaked at $4.4 million in Q4 2024 and troughed at $2.6 million in Q2 2022.
  • A 5-year average of $2.8 million and a median of $2.6 million in 2022 define the central range for Other Non-Current Assets.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 64.75% in 2024 and later tumbled 40.53% in 2025.
  • Year by year, Other Non-Current Assets stood at $2.6 million in 2022, then increased by 2.06% to $2.7 million in 2023, then soared by 64.75% to $4.4 million in 2024, then tumbled by 40.53% to $2.6 million in 2025, then soared by 55.88% to $4.1 million in 2026.
  • Business Quant data shows Other Non-Current Assets for ZNTL at $4.1 million in Q1 2026, $2.6 million in Q4 2025, and $2.6 million in Q3 2025.